These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1252 related articles for article (PubMed ID: 33910272)

  • 1. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation between Immune Microenvironment Features and EGFR Mutation Status 
in Lung Adenocarcinoma].
    Zhu H; Chen P; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Yuan F; Yu X; Sun Q; Ji J; Wang S; Liu T; Xu L
    Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):204-216. PubMed ID: 37035883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
    Kawana S; Saito R; Miki Y; Kimura Y; Abe J; Sato I; Endo M; Sugawara S; Sasano H
    Cancer Med; 2021 Jan; 10(2):718-727. PubMed ID: 33305905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 7. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
    Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
    Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in Immunological Landscape between
    Luo JW; Guo YH; Wu FY; Li XF; Sun XC; Wang JL; Zhou CC
    Dis Markers; 2021; 2021():3776854. PubMed ID: 34484468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of RASGRP2 in Lung Adenocarcinoma and Its Effect 
on Immune Microenvironment].
    Zhao S; Jin X; Xu S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):404-411. PubMed ID: 34157800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 13. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
    BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
    Xia W; Mao W; Chen R; Lu R; Liu F; He Y; Wang S; Li X; Zheng M
    Med Sci Monit; 2019 Nov; 25():8764-8776. PubMed ID: 31746315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma.
    Gong Z; Chen J; Cheng JN; Sun C; Jia Q; Diao X; Zhu B
    Clin Lung Cancer; 2018 Sep; 19(5):e551-e558. PubMed ID: 29628320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 19. EGFR mutations induce the suppression of CD8
    Huang H; Zhu X; Yu Y; Li Z; Yang Y; Xia L; Lu S
    J Transl Med; 2024 Jul; 22(1):653. PubMed ID: 39004699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
    Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
    Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.